First-in-Human Study of the Oral ALK Inhibitor Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
First-in-Human Study of the Oral ALK Inhibitor Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Roy S Herbst, MD, PhD (6/23/10), Corey J Langer, MD (7/2/10) and Lecia V Sequist, MD, MPH (6/18/10)
Bang Y et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Proc ASCO 2010;Abstract 3. |
||||||||